Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNG | P07510 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRND | Q07001 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405408 | 0.90 | CHRNB2 (0.50) | CHRNB2CHRNA4CYP11B2PIK3CGCHRNB4 | |
| SCHEMBL5405224 | 0.87 | CHRNB2 (0.59) | CHRNB2CHRNA4CYP11B2CYP11B1CHRNA1 | |
| SCHEMBL5416033 | 0.83 | CHRNB2 (0.51) | CHRNB2CHRNA4CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL5729484 | 0.80 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1813296 | 0.79 | ALOX5 (0.46) | — | |
| SCHEMBL29959593 | 0.79 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL161236 | 0.79 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL11544331 | 0.79 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1462348 | 0.77 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30241910 | 0.77 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | PETERS DAN | 2007-07-12 | — | — | US | claimed |
| US-6756386-B1 | SUCH AS 1-METHYL-3-OXY-(5-CHLORO-3-PYRIDYL)-PIPERIDINE; CHOLINERGIC SYSTEM OF CENTRAL NERVOUS SYSTEM; PAIN, INFLAMMATION | NEUROSEARCH A/S (DK) | 2004-06-29 | — | — | US | claimed |
| EP-1357121-A1 | Azaring-ether deritatives and their use as nicotinic ach receptor modulators | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | claimed |
| EP-1034174-B1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2003-08-13 | — | — | EP | claimed |
| EP-1034174-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2000-09-13 | — | — | EP | claimed |
| WO-1999024422-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-05-20 | — | — | WO | claimed |
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | PETERS DAN | 2007-07-12 | — | — | US | disclosed |
| US-7202237-B2 | Pyridylether derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20040242558-A1 | Pyridylether derivatives, their preparation and use | NEUROSEARCH A/S | 2004-12-02 | — | — | US | disclosed |
| US-6756386-B1 | SUCH AS 1-METHYL-3-OXY-(5-CHLORO-3-PYRIDYL)-PIPERIDINE; CHOLINERGIC SYSTEM OF CENTRAL NERVOUS SYSTEM; PAIN, INFLAMMATION | NEUROSEARCH A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| EP-1357121-A1 | Azaring-ether deritatives and their use as nicotinic ach receptor modulators | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | disclosed |
| EP-1034174-B1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2003-08-13 | — | — | EP | disclosed |
| EP-1034174-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999024422-A1 | AZARING-ETHER DERIVATIVES AND THEIR USE AS NICOTINIC ACH RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161614-A1 | Pyridylether derivatives, their preparation and use | CHRNA4, CHRNA5, CHRM3 | CHRNB2 18/4885CHRNA4 1/4885CYP11B2 756/4885 |
| US-20040242558-A1 | Pyridylether derivatives, their preparation and use | CHRNA4, CHRNA5, CHRM3 | CHRNB2 18/4885CHRNA4 1/4885CYP11B2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.